Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat and prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia (serum potassium < 3.5 mEq/L) * Prevention of hypokalemia in patients at risk ## Adult Dosing **Oral:** * **Treatment of hypokalemia:** Typically 20-60 mEq per day in divided doses. Doses up to 100 mEq per day may be required in severe cases. * **Prevention of hypokalemia:** Typically 20 mEq per day. **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing is guided by serum potassium levels and clinical status. Common regimens range from 10-40 mEq per dose. * **Mild to moderate hypokalemia (serum K 2.5-3.5 mEq/L):** 20-40 mEq can be added to a liter of IV fluid and infused over 4-10 hours. * **Severe hypokalemia (serum K < 2.5 mEq/L):** Dosing up to 60-100 mEq may be necessary. * **Maximum infusion rate:** Generally should not exceed 10-20 mEq per hour peripherally and up to 40 mEq per hour centrally for severe, life-threatening hypokalemia, with continuous cardiac monitoring. Higher rates require extreme caution and close monitoring. * **Maximum concentration:** Peripheral IV: 40 mEq/L. Central IV: 60-80 mEq/L, but concentrations > 40 mEq/L increase phlebitis risk. Dosing for specific IV regimens will depend on local hospital protocol and physician orders. ## Pediatric Dosing **Oral:** * **Treatment of hypokalemia:** 1-3 mEq/kg/day divided into 2-4 doses. Maximum dose 20 mEq/day for infants and children. * **Prevention of hypokalemia:** 0.5-1 mEq/kg/day. **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing is highly individualized based on serum potassium, age, and weight. Typical starting doses are 0.5-1 mEq/kg per dose, infused over 1-3 hours. * **Maximum infusion rate:** Generally 0.5-1 mEq/kg/hour, but may be increased to 2 mEq/kg/hour in critical hypokalemia with continuous ECG monitoring. * **Maximum concentration:** Typically 40 mEq/L. Specific pediatric IV dosing protocols vary significantly. ## Dose Adjustments * **Renal impairment:** Reduce dose and monitor potassium closely. Severe renal impairment may preclude potassium supplementation. * **Adrenal insufficiency:** May require lower doses. ## Contraindications * Hyperkalemia (serum potassium > 5 mEq/L) * Conditions that predispose to hyperkalemia (e.g., untreated Addison's disease, severe renal impairment, acute dehydration, extensive tissue breakdown) * Known hypersensitivity to potassium chloride ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal discomfort. * **Serious:** Hyperkalemia (most significant risk), cardiac arrhythmias, cardiac arrest, intestinal obstruction or perforation (with oral sustained-release formulations). ## Key Drug Interactions * **Potassium-sparing diuretics** (e.g., spironolactone, amiloride, triamterene) and **ACE inhibitors**, **ARBs**, **NSAIDs**, **heparin**, **cyclosporine**, **tacrolimus:** Increased risk of hyperkalemia. * **Aldosterone antagonists:** Increased risk of hyperkalemia. * **Insulin:** Can shift potassium intracellularly, temporarily lowering serum potassium. * **Digoxin:** Hyperkalemia may increase digoxin toxicity; hypokalemia may decrease digoxin toxicity. ## Monitoring * **Serum potassium:** Frequently, especially during IV administration and dose titration. * **Renal function (BUN, creatinine):** Prior to and during therapy. * **ECG:** For signs of hyperkalemia (peaked T waves, prolonged PR interval, widened QRS) especially with rapid IV infusion or in patients with cardiac history. * **Urine output:** To assess renal function. ## Clinical Pearls * Oral potassium supplements should be taken with food or a meal to minimize gastrointestinal upset. * Sustained-release oral formulations carry a risk of gastrointestinal ulceration or obstruction; they should not be used in patients with decreased gastrointestinal motility. * Rapid IV infusion can be dangerous and cause cardiac arrest. Always follow recommended infusion rates and concentrations. * Correcting magnesium deficiency is often necessary to effectively replete potassium, as magnesium is a cofactor for potassium repletion. * Oral administration is preferred when possible due to safety. *** *This information is intended for healthcare professionals. Always verify current prescribing information with the official drug labeling and relevant clinical guidelines.*